Latest Pertuzumab Stories
RnRMarketResearch.com adds “Perjeta & Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023” to its store.
DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports
Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to research results released on Sunday.
MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A.
Active research in breast cancer is producing novel targeted drugs at a rapid pace. Thousand Oaks, California (PRWEB) April 03, 2014 As the Cancer society
MarketResearchReports.Biz announces addition of new report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions
A recent FDA-approved combination of therapies used to target HER2-positive breast cancer does not lead to increased cardiac problems for patients, but doctors should regularly perform cardiac
- totally perplexed and mixed up.